Silexion Therapeutics Corp 8-K

What Happened
Silexion Therapeutics Corp (SLXN) filed a Form 8-K on April 28, 2026 to disclose that it issued a press release announcing the successful submission of a Phase 2/3 clinical trial application (CTA) to Germany’s Federal Institute for Drugs and Medical Devices (BfArM) for its drug candidate SIL204. The CTA is for a study in KRAS-driven locally advanced pancreatic cancer. The press release is furnished as Exhibit 99.1 to the Form 8-K.

Key Details

• Date filed: April 28, 2026 (Form 8-K, Item 7.01 — Regulation FD Disclosure).
• Submission: Phase 2/3 clinical trial application (CTA) to Germany’s BfArM for SIL204.
• Indication: KRAS-driven locally advanced pancreatic cancer.
• Press release announcing the submission is included as Exhibit 99.1 to the 8-K.

Why It Matters
This is a regulatory and development milestone for Silexion: submission of a Phase 2/3 CTA is a necessary step toward starting a pivotal trial in the EU, which could advance SIL204’s clinical program if the CTA is accepted. For investors, the update signals progress in the company’s pipeline but does not by itself provide trial timelines, acceptance status, clinical data, or financial commitments; those details would appear in future company disclosures.